Electrochemiluminescence assay for basic carboxypeptidases: Inhibition of basic carboxypeptidases and activation of thrombin-activatable fibrinolysis inhibitor

Analytical Biochemistry

Volumn 319, Issue 1, 2003, Pages 159-170

  Mao, Shi Shan ^a   Colussi, Dennis ^a   Bailey, Carolyn M ^a   Bosserman, Michele ^a   Burlein, Christine ^a   Gardell, Stephen J ^a,b   Carroll, Steven S ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b BAYER CORPORATION   (United States)

Author keywords

Carboxypeptidase; Electrochemiluminescence; Inhibition; Protein isolation; TAFI; Thrombin activatable fibrinolysis inhibitor

Indexed keywords

AMINO ACIDS; ANTIBODIES; CHEMICAL DETECTION; ENZYME INHIBITION; EPITOPES; PEPTIDES;

CARBOXYPEPTIDASE; ELECTROCHEMILUMINESCENCE; PROTEIN ISOLATION; TAFI; THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ENZYMES;

AMINOCAPROIC ACID; ARGININE; CARBOXYPEPTIDASE; CARBOXYPEPTIDASE B; EPITOPE; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ACCURACY; AMINO ACID SEQUENCE; ANTIGEN BINDING; ARTICLE; BLOOD ANALYSIS; CARBOXY TERMINAL SEQUENCE; CHEMOLUMINESCENCE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME ASSAY; ENZYME INHIBITION; ENZYME STABILITY; ENZYME SUBSTRATE; HUMAN; IMMUNOASSAY; PRIORITY JOURNAL; PROTEIN ISOLATION; SERUM;

ANIMALIA;

EID: 0038691686     PISSN: 00032697     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-2697(03)00252-5     Document Type: Article

References (49)

1. Skidgel R.A. Structure and function of mammalian zinc carboxypeptidases. Hooper N.M. Zinc Metalloproteins in Health and Disease. 1996;241-283 Taylor & Francis Ltd. London. (Chapter 10).
2. Reznik S.E., Fricker L.D. Carboxypeptidases from A to Z: implications in embryonic development and Wnt binding. Cell. Mol. Life Sci. 58:2001;1790-1804.
3. Skidgel R.A. Basic carboxypeptidases: regulators of peptide hormone activity. Trends Pharmacol. Sci. 9:1988;299-304.
4. Fricker L.D., Leiter E.H. Peptides, enzymes and obesity: new insights from a "Dead" enzyme. Trends Biochem. Sci. 24:1999;390-393.
5. Skidgel R.A. Bradykinin-degrading enzymes: structure, function, distribution, and potential roles in cardiovascular pharmacology. J. Cardiovasc. Pharmacol. 20(Suppl. 9):1992;S4-S9.
6. Song L., Fricker L.D. Cloning and expression of human carboxypeptidase Z, a novel metallocarboxypeptidase. J. Biol. Chem. 272:1997;10543-10550.
7. Boffa M.B., Nesheim M.E., Koschinsky M.L. Thrombin-activatable fibrinolysis inhibitor (TAFI): molecular genetics of an emerging potential risk factor for thrombotic disorders. Curr. Drug Targets-Cardiovasc. Haematol. Disorder. 1:2001;59-74.
8. Bouma B.N., Marx P.F., Mosnier L.O., Meijers J.C.M. Thrombin-activatable fibrinolysis inhibitor (TAFI, Plasma Procarboxypeptidase B, Procarboxypeptidase R, Procarboxypeptidase U). Thromb. Res. 101:2001;329-354.
9. Nesheim M., Wang W., Boffa M., Nagashima M., Morser J., Bajzar L. Thrombin, thrombomodulin, and TAFI in the molecular link between coagulation and fibrinolysis. Thromb. Haemost. 78:1997;386-391.
10. Hendriks D., Wang W., Scharpe S., Lommaert M.-P., van Sande M. Purification and characterization of a new arginine carboxypeptidase in human serum. Biochim. Biophys. Acta. 1034:1990;86-92.
11. Campbell W., Okada H. An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits. Biochem. Biophys. Res. Commun. 162:1989;933-939.
12. Eaton D.L., Malloy B.E., Tsai S.P., Henzel W., Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J. Biol. Chem. 266:1991;21833-21838.
13. Suenson E., Lutzen O., Thorsen S. Initial plasmin-degradation of fibrin as the basis of a positive feed-back mechanism in fibrinolysis. Eur. J. Biochem. 140:1984;513-522.
14. Bajzar L., Manuel R., Nesheim M.E. Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J. Biol. Chem. 270:1995;14477-14484.
15. Bajzar L., Morser J., Nesheim M.E. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J. Biol. Chem. 271:1996;16603-16608.
16. Mao S.-S., Cooper C.M., Wood T., Shafer J.A., Gardell S.J. Characterization of plasmin-mediated activation of plasma procarboxypeptidase B. J. Biol. Chem. 274:1999;35046-35052.
17. Marx P.F., Dawson P.E., Bouma B.N., Meijers J.C.M. Plasmin-mediated activation and inactivation of thrombin-activatable fibrinolysis inhibitor. Biochemistry. 41:2002;6688-6696.
18. Boffa M.B., Wang W., Bajzar L., Nesheim M.E. Plasma and recombinant thrombin-activatable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties. J. Biol. Chem. 273:1998;2127-2135.
19. Marx P.F., Hackeng T.M., Dawson P.E., Griffin J.H., Meijers J.C.M., Bouma B.N. Inactivation of active thrombin-activatable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage. J. Biol. Chem. 275:2000;12410-12415.
20. Wang W., Hendriks D.F., Scharpe S.S. Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen. J. Biol. Chem. 269:1994;15937-15944.
21. Schatteman K.A., Goossens F.J., Leurs J., Kasahara Y., Scharpe S.S., Hendriks D.F. Fast homogeneous assay for plasma procarboxypeptidase U. Clin. Chem. Lab. Med. 39:2001;806-810.
22. Plummer T.H., Kimmel M.T. An improved spectrophotometric assay for human plasma carboxypeptidase N. Anal. Biochem. 108:1980;348-353.
23. Mock W.L., Stanford D.J. Anisylazoformylarginine: a superior assay substrate for carboxypeptidase B type enzymes. Bioorg. Med. Chem. Lett. 12:2002;1193-1194.
24. Fricker L.D. Methods for studying carboxypeptidase E. Methods Neurosci. 23:1995;237-250.
25. Tan F., Deddish P.A., Skidgel R.A. Human carboxypeptidase M. Methods Enzymol. 248:1995;663-675.
26. Novikova E.G., Fricker L.D. Purification and characterization of human metallocarboxypeptidase Z. Biochem. Biophys. Res. Commun. 256:1999;564-568.
27. Yang H., Leland J.K., Yost D., Massey R.J. Electrochemiluminescence: a new diagnostic and research tool. Bio/Technology. 12:1994;193-194.
28. Li Y., Xu M., Lai M.-T., Huang Q., Castro J.L., DiMuzio-Mower J., Harrison T., Lellis C., Nadin A., Neduvelil J.G., Register R.B., Sardana M.K., Shearman M.S., Smith A.L., Shi X.-P., Yin K.-C., Shafer J.A., Gardell S.J. Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1. Nature. 405:2000;689-694.
29. Plummer T.H., Ryan T.J. A potent mercapto bi-product analogue inhibitor for human carboxypeptidase N. Biochem. Biophys. Res. Commun. 98:1981;448-454.
30. March S.C., Parikh I., Cuatrecasas P. A simplified method for cyanogen bromide activation of agarose for affinity chromatography. Anal. Biochem. 60:1974;149-152.
31. Ager S.P., Hass G.M. Affinity chromatography of pancreatic carboxypeptidases using a carboxypeptidase inhibitor from potatoes as ligand. Anal. Biochem. 83:1977;285-295.
32. Zhang L., Schwartz G., O'Donnell M., Harrison R.K. Development of a novel helicase assay using electrochemiluminescence. Anal. Biochem. 293:2001;31-37.
33. Rogers M.V. Light on high-throughput screening: fluorescence-based assay technologies. Drug Discov. Today. 2:1997;156-160.
34. Beaudet L., Bedard J., Breton B., Mercuri R.J., Budarf M.L. Homogeneous assays for single-nucleotide polymorphism typing using AlphaScreen. Genome Res. 11:2001;600-608.
35. Tang F., Jackman H., Skidgel R.A., Zsigmond E.K., Erdos E.G. Protamine inhibits plasma carboxypeptidase N, the inactivator of anaphylatoxins and kinins. Anesthesiology. 70:1989;267-275.
36. Marx P.F., Wagenaar G.T.M., Reijerkerk A., Tiekstra M.J., van Rossum A.G.S.H., Gebbink M.F.B.G., Meijers J.C.M. Characterization of mouse thrombin-activatable fibrinolysis inhibitor. Thromb. Haemost. 83:2000;297-303.
37. Hendriks D., Scharpe S., van Sande M., Lommaert M.P. Characterization of a carboxypeptidase in human serum distinct from carboxypeptidase N. J. Clin. Chem. Clin. Biochem. 27:1989;277-285.
38. Schatteman K.A., Goossens F.J., Scharpe S.S., Hendriks D.F. Activation of plasma procarboxypeptidase U in different mammalian species points to a conserved pathway of inhibition of fibrinolysis. Thromb. Haemost. 82:1999;1718-1721.
39. Hung A.Y., Sheng M. PDZ domains: structural modules for protein complex assembly. J. Biol. Chem. 277:2002;5699-5702.
40. Ferrer M., Hamilton A.C., Inglese J. A PDZ domain-based detection system for enzymatic assays. Anal. Biochem. 301:2002;207-216.
41. Huey R., Bloor C.M., Kawahara M.S., Hugli T.E. Potentiation of the anaphylatoxins in vivo using an inhibitor of serum carboxypeptidase N (SCPN). Am. J. Pathol. 112:1983;48-60.
42. Lowenstein E., Johnston W.E., Lappas D.G., D'Ambra M.N., Schneider R.C., Daggett W.M., Akins C.W., Philbin D.M. Catastrophic pulmonary vasoconstriction associated with protamine reversal of heparin. Anesthesiology. 59:1983;470-473.
43. Cambell W., Okada N., Okada H. Carboxypeptidase R is an inactivator of complement-derived inflammatory peptides and an inhibitor of fibrinolysis. Immunol. Rev. 180:2001;162-167.
44. Meijers J.C.M., Tekelenburg W.L.H., Bouma B.N., Bertina R.M., Rosendaal F.R. High levels of coagulation factor XI as a risk factor for venous thrombosis. N. Engl. J. Med. 342:2000;696-701.
45. Antovic J., Schulman S., Eelde A., Blomback M. Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A. Haemophilia. 7:2001;557-560.
46. Mosnier L.O., Lisman T., van den Berg H.M., Nieuwenhuis H.K., Meijers J.C.M., Bouma B.N. The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration. Thromb. Haemost. 86:2001;1035-1039.
47. van Tilburg N.H., Rosendaal F.R., Bertina R.M. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood. 95:2000;2855-2859.
48. Juhan-Vague I., Morange P.E., Aubert H., Henry M., Ailaud M.F., Alessi M.C., Samnegard A., Hawe E., Yudkin J., Margaglione M., Di Minno G., Hamsten A., Humphries S.E. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler. Thromb. Vasc. Biol. 22:2002;867-873.
49. Tan A.K., Eaton D.L. Activation and characterization of procarboxypeptidase B from human plasma. Biochemistry. 34:1995;5811-5816.